Percutaneous Interventions in the Coagulopathic Patient

ABSTRACT

Interventional procedures in patients with coagulopathies carry a perceived risk of increased bleeding and complications. Acquired and inherited deficiencies of blood-clotting factors, thrombocytopenia and platelet dysfunction, and effect of anticoagulation are common problems encountered by practicing clinical interventional radiologists. In this article we review common coagulopathies, available data on percutaneous procedures in coagulopathic patients, and recommendations for periprocedure treatment.

Interventional radiology - coagulopathy - complications - thrombocytopenia - review

REFERENCES

• 1 Rodgers R P, Levin J. A critical reappraisal of the bleeding time.  Semin Thromb Hemost. 1990;  16 1-20
• 2 Favaloro E J. Clinical application of the PFA-100.  Curr Opin Hematol. 2002;  9 407-415
• 3 Liu M C, Kessler C M. A systematic approach to the bleeding patient. In: Kitchens CS, Alving BA, Kessler CM Consultative Hemostasis and Thrombosis. Philadelphia; WB Saunders 2002: 27-39
• 4 Rao A K. Acquired qualitative platelet defects. In: Colman RW, Marder VJ, Clowes P, George JN Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Philadelphia; Lippincott Williams & Wilkins 2001: 905-920
• 5 Stanworth S J, Brunskill S J, Hyde C H, McClelland D BL, Murphy M F. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials.  Br J Haematol. 2004;  126 139-152
• 6 McVay P A, Toy P TCY. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities.  Am J Clin Pathol. 1990;  94 747-753
• 7 Fisher N C, Mutimer D J. Central venous cannulation in patients with liver disease and coagulopathy-a prospective audit.  Intensive Care Med. 1999;  25 481-485
• 8 McVay P A, Toy P T. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities.  Transfusion. 1991;  31 164-171
• 9 Chowdhury P, Saayman A G, Paulua U, Findlay G P, Collins P W. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients.  Br J Haematol. 2004;  125 69-73
• 10 Youssef W I, Salazar F, Dasarathy S, Beddow T, Mullen K D. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study.  Am J Gastroenterol. 2003;  98 1391-1394
• 11 Kuriyan M, Carson J L. Blood transfusion risks in the intensive care unit.  Crit Care Clin. 2004;  20 237-253
• 12 Slichter S J. Relationship between platelet count and bleeding risk in thrombocytopenic patients.  Transfus Med Rev. 2004;  18 153-167
• 13 Wallace M J, Narvios A, Lichtiger B et al.. Transjugular liver biopsy in patients with hematologic malignancy and severe thrombocytopenia.  J Vasc Interv Radiol. 2003;  14 323-327
• 14 Vavricka S R, Walter R B, Irani S, Halter J, Schanz U. Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion.  Ann Hematol. 2003;  82 570-573
• 15 Ray Jr C E, Shenoy S S. Patients with thrombocytopenia: outcome of radiologic placement of central venous access devices.  Radiology. 1997;  204 97-99
• 16 Kitchens C S. Surgery and hemostasis. In: Kitchens CS, Alving BA, Kessler CM Consultative Hemostasis and Thrombosis. Philadelphia; WB Saunders 2002: 463-480
• 17 Aster R H. Pooling of platelet in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia.  J Clin Invest. 1966;  45 645-657
• 18 Mannucci P M. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.  Blood. 1997;  90 2515-2521
• 19 Rao A K, Ghosh S, Sun L et al.. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects: a double-blind placebo-controlled trial.  Thromb Haemost. 1995;  74 1071-1078
• 20 Reiter R A, Mayr F, Blazicek H et al.. Desmopressin antagonizes the in vitro platelet dysfunction induced by GpIIb/IIIa inhibitors and aspirin.  Blood. 2003;  102 4594-4599
• 21 Lethagen S. Desmopressin-a haemostatic drug: state-of-the-art review.  Eur J Anaesthesiol Suppl. 1997;  14 1-9
• 22 Dickneite G, Metzner H, Pfeifer T, Kroez M, Witzke G. A comparison of fibrin sealants in relation to their in vitro and in vivo properties.  Thromb Res. 2003;  112 73-82
• 23 Tock B, Drohan W, Hess J, Pusateri A, Holcomb J, MacPhee M. Haemophilia and advanced fibrin sealant technologies.  Haemophilia. 1998;  4 449-455
• 24 Martinowitz U, Varon D, Jonas P et al.. Circumcision in hemophilia: the use of fibrin glue for local hemostasis.  J Urol. 1992;  148 855-857
• 25 Brady A P, Malone D E, Diegnan R W, O'Donovan N, McGrath F P. Fibrin sealant in interventional radiology: a preliminary evaluation.  Radiology. 1995;  196 573-578
• 26 DiMichele D M, Mirani G, Wilfredo Canchis P, Trost D W, Talal A H. Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection.  Haemophilia. 2003;  9 613-618
• 27 Menzebach A, Cassens U, van Aken H, Booke M. Strategies to reduce perioperative blood loss related to non-surgical bleeding.  Eur J Anaesthesiol. 2003;  20 764-770
• 28 Key N S. Recombinant FVIIa for intractable hemorrhage: more questions than answers.  Transfusion. 2003;  43 1649-1651
• 29 Friederich P W, Henny C P, Messelink E J et al.. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomized trial.  Lancet. 2003;  361 201-205
• 30 Deveras R AE, Kessler C M. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate.  Ann Intern Med. 2002;  137 884-888
• 31 Jeffers L, Chalasani N, Balart N, Pyrsopoulos N, Erhardtsen E. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy.  Gastroenterology. 2002;  123 118-126